Related Experiment Video

Updated: Nov 26, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.4K

Possible immune regulation mechanisms for the progression of chronic thromboembolic pulmonary hypertension

Ran Miao1, Xingbei Dong2, Juanni Gong3

  • 1Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Institute of Respiratory Medicine, Beijing 100020, China.

Thrombosis Research
|December 14, 2020
PubMed

Insights

This study identified key genes and immune cell interactions involved in chronic thromboembolic pulmonary hypertension (CTEPH). Glufosfamide and Kifunensine show potential as novel therapeutic drugs for CTEPH treatment.

Area of Science:

  • Immunology
  • Genomics
  • Pharmacology

Background:

  • Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe condition with complex underlying mechanisms.
  • Understanding the genetic and immune factors in CTEPH is crucial for developing effective treatments.

Purpose of the Study:

  • To identify key genes associated with CTEPH using an immune cell-centric approach.
  • To predict potential therapeutic drugs for CTEPH based on gene-drug interactions.

Main Methods:

  • Analysis of differentially expressed genes (DEGs) in CTEPH patient data.
  • Construction of circRNA-miRNA-mRNA and protein-protein interaction (PPI) networks.
  • Prediction and verification of drug-gene interactions.

Main Results:

  • Five key immune cell-related DEGs were identified, including solute carrier family 2 member 3 (SLC2A3).
  • Specific circRNA-miRNA-mRNA interactions (e.g., circ_0022342-miR-503-5p-SLC2A3) were elucidated.
  • Glufosfamide and Kifunensine were predicted as potential drugs for CTEPH.

Conclusions:

  • SLC2A3 and MAN2A1 are implicated in CTEPH pathogenesis.
  • Identified molecular pathways may reveal immune regulation mechanisms in CTEPH.
  • Findings offer insights for CTEPH diagnosis and treatment from an immunological perspective.
Abstract

Keywords:
Chronic thromboembolic pulmonary hypertensionCircular RNADifferentially expressed geneImmune cellmicroRNA

More Related Videos

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.7K
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

17.2K

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
430
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
319
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
127
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
142
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
124